Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of quetiapine fumarate
(Seroquel) with daily dose 600mg-750mg used as mono-therapy in the treatment of acute
schizophrenic patients by evaluation of the change from baseline in PANSS total score at Day
56 using the last observation carried forward (LOCF) method.